Cencora, Inc. (NYSE:COR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Cencora, Inc. (NYSE:COR) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $277.90.

COR has been the topic of several recent analyst reports. Evercore ISI upped their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. StockNews.com downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Finally, Wells Fargo & Company upped their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th.

Cencora Stock Up 0.3 %

COR stock opened at $254.54 on Wednesday. The company’s 50 day simple moving average is $244.34 and its 200-day simple moving average is $238.39. The firm has a market capitalization of $49.36 billion, a PE ratio of 36.21, a P/E/G ratio of 1.31 and a beta of 0.51. Cencora has a 12 month low of $214.77 and a 12 month high of $262.26. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities analysts expect that Cencora will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio is currently 31.29%.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the sale, the chief executive officer now owns 51,070 shares of the company’s stock, valued at $13,022,850. This represents a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,648 shares of company stock valued at $2,862,342 over the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

Several large investors have recently made changes to their positions in COR. JFS Wealth Advisors LLC increased its position in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after acquiring an additional 46 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Cencora during the 4th quarter valued at $29,000. SBI Securities Co. Ltd. acquired a new stake in Cencora during the 4th quarter valued at $30,000. Householder Group Estate & Retirement Specialist LLC grew its holdings in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Finally, Kentucky Trust Co acquired a new stake in Cencora during the 4th quarter valued at $33,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.